Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III

Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncologicas Carlos III (f.s.p. Cnio)

Centro Nacional De Investigaciones Oncologicas (cnio)

Joaquín Pastor Fernández

Guido Kurz

Sonia Martínez González

Carmen Blanco Aparicio

Jose Ignacio Martín Hernando

Antonio Rodríguez Hergueta

Rosario Concepción Riesco Fagundo

Ana Isabel Hernández Higueras

Francisco Javier Ramos Lima

Ana Maria Garcia Collazo

Julen Oyarzabal Santamarina

Ana Belén García García

David Álvaro Cebrián Muñoz

David Alvaro Cebrián Muñoz

Manuel Serrano Marugan

Sonia Martínez Gonzalez

Ana Ortega Molina

Carl-Gustave Pierre Saluste

Esther Gonzalez Cantalapiedra

Cristina Ana Gómez De La Oliva

James R Bischoff

Antonio Salgado Serrano

Beatriz Noya Marino

Oscar Fernández-Capetillo Ruiz

Rosa María Álvarez Escobar

María Del Rosario Rico Ferreira

Virginia Rivero Buceta

Luis Ignacio Toledo Lázaro

Sonsoles Rodríguez Arísteguí

María Nieto Soler

Matilde Murga Costa

Carmen Varela Busto

Carmen Blanco-Aparicio

Andrés Joaquín Lopez Contreras

Oliver Renner

Esther González Cantalapiedra

Ana Belén GARCÍA GARCÍA

David ÁLvaro CEBRIÁN MUÑOZ

Rosa María ÁLvarez Escobar

José Ignacio MARTÍN Hernando

Rosa María Alvarez Escobar

Esther GONZÁLES Cantalapiedra

Sonsoles RODRÍGUEZ Aristegui

Beatriz Noya Mariño

There is provided compounds of formula I, wherein R, R, RR, R, R, Rand Rhave meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8 and/or Haspin kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

Condensed tricyclic compounds as protein kinase inhibitors

There is provided compounds of formula I, wherein R1, R, R, R, X, Y, Z, Rand ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds. 

Macrocyclic compounds as protein kinase inhibitors

There is provided compounds of formula (I), wherein R, R, Rand Rhave meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I). 

Tricyclic compounds for use as kinase inhibitors

Provided are chemical entities selected from compounds of formula (I), wherein R, Rand m have meanings given in the description, and pharmaceutically acceptable salts, solvates and stereoisomers thereof, which are inhibitors of ATR and are potentially useful in the treatment of cancer. Further provided are pharmaceutical compositions of the chemical entities, combination products containing the chemical entities, the use of the compositions as therapeutic agents, and methods of treatment using these compositions. 

Chemical entities

Growing community of inventors

Madrid, Spain

Joaquín Pastor Fernández